Topic: patent infringement
In a high-stakes patent lawsuit between CAR-T companies Bristol-Myers Squibb and Gilead Sciences, BMS has come up with a victory.
Teva’s $235 million win in a GlaxoSmithKline patent infringement case was a big victory—but now, one appeals court judge is “baffled” by the decision.
As a high-profile PCSK9 patent battle plays out in the U.S., Amgen won an injunction in Germany blocking Praluent, Sanofi and Regeneron's rival med.
Swamped with generics, Eli Lilly’s Cialis is on the ropes. But to protect its Cialis patent in prostate disease, Lilly is taking the fight to SCOTUS.
A jury ordered Takeda, which just scooped up Shire, to pay $155 million for stepping on Bayer's hemophilia patent.
Monday was a good-news-bad-news day for Gilead as the Supreme Court handed down two decisions about which appeals they'll consider.
Prove it, GSK. So says a judge in the Coreg "carve-out" patent case that last year ended in a $235 million judgment against generics maker Teva.
Novartis is suing Regeneron for patent infringement over the manufacturing process of its Eylea and Zaltrap eye treatments.
The patent pillars that have supported Teva’s defense of blockbuster Copaxone continue to fall with Mylan winning another legal battle In the U.K.
An appeals court today tossed out a ban on Sanofi and Regeneron’s cholesterol drug Praluent and ordered a new trial in the patent fight with Amgen.